Long-term outcome of patients with ANCA-associated vasculitis treated with plasma exchange: a retrospective, single-centre study

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F16%3A00059980" target="_blank" >RIV/00023001:_____/16:00059980 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11110/16:10325549 RIV/00064165:_____/16:10325549
Result on the web
<a href="http://arthritis-research.biomedcentral.com/articles/10.1186/s13075-016-1055-5" target="_blank" >http://arthritis-research.biomedcentral.com/articles/10.1186/s13075-016-1055-5</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1186/s13075-016-1055-5" target="_blank" >10.1186/s13075-016-1055-5</a>

Result language
angličtina
Original language name
Long-term outcome of patients with ANCA-associated vasculitis treated with plasma exchange: a retrospective, single-centre study
Original language description
Background: Plasma exchange (PLEX) has been used routinely for treatment of severe renal vasculitis and/or alveolar haemorrhage (AH) in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), but the long-term benefit of PLEX in AAV remains unclear. We aimed to describe the characteristics and outcomes of patients treated with PLEX in a single centre. Conclusions: The mortality of patients presenting with severe manifestations of AAV remains high despite the use of PLEX. Older age at presentation is associated with worse overall and renal prognosis.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FE - Other fields of internal medicine
OECD FORD branch
—

Publication year
2016
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)